Last updated: July 28, 2026
Warner Chilcott v. Teva Pharmaceuticals USA (15-1588): Litigation Summary, Claims at Issue, and Exclusivity Impact
Executive summary: The U.S. Court of Appeals for the Federal Circuit docket 15-1588 reflects appellate litigation between Warner Chilcott Company, LLC and Teva Pharmaceuticals USA, Inc.. A litigation summary and analysis that is accurate and decision-grade requires the case caption details, claim construction record, district court judgment, asserted patents (numbers), and the Federal Circuit disposition. Without those specifics, any narrative would risk misidentifying the patents, the legal issues (e.g., § 271(e)(2), § 156, or obviousness), and the resulting exclusivity or generic-launch exposure.
What patents were litigated in Warner Chilcott Co. LLC v. Teva (15-1588)?
A litigation-grade patent summary must identify:
- Asserted patent numbers (and title/priority where relevant)
- Asserted claims (independent vs dependent)
- Orange Book listing(s) tied to the NDA/ANDA product(s)
- Alleged infringement theory (literal, doctrine of equivalents, or inducement)
- District court’s claim construction that drove the infringement/non-infringement finding
No patent identifiers or claim-level information are provided with the docket reference alone, so the litigation scope cannot be mapped to an accurate patent estate.
Which drug product and ANDA/NDA regulatory context drove 15-1588?
To connect the appeal to FDA exclusivity and generic entry timing, the record must tie 15-1588 to:
- NDA brand and active ingredient
- ANDA filer(s) and filing date(s)
- Paragraph IV notice(s) and validity/invalidity theories
- Whether the appeal concerns infringement, validity, or eligibility for exclusivity adjustments
No such regulatory context is included.
What happened procedurally in Federal Circuit appeal 15-1588?
A complete procedural timeline requires:
- District court jurisdiction and case number
- Final judgment date and summary of holdings
- Whether the appeal is from a preliminary injunction, a final infringement/validity decision, or a dismissal/transfer order
- Standards of review applied by the Federal Circuit (claim construction, obviousness, enablement, indefiniteness, etc.)
Was 15-1588 about validity, non-infringement, or exclusivity?
Those are distinct issue tracks. The correct classification determines:
- Whether the decision created a freedom-to-operate green light for the generic
- Whether the ruling narrowed the patent claims via claim construction
- Whether the ruling strengthened the patent estate for other generics or later challenges
The docket reference alone does not provide the issue posture.
How strong is the patent estate in the Warner Chilcott vs Teva dispute?
Patent-estate strength depends on decision specifics:
- Which claims survived or were invalidated
- Whether invalidity was based on anticipation/obviousness, lack of written description, enablement, indefiniteness, or nonstatutory subject matter
- Whether the Federal Circuit affirmed or reversed and on what legal reasoning
Which claim scope survived the appeal (if any)?
Without the Federal Circuit outcome text, it is not possible to state:
- Whether the asserted claims were affirmed as infringed/valid
- Whether claim construction limited infringement
- Whether the patents remain enforceable for licensing and enforcement strategies
What is the Orange Book status of the Warner Chilcott patents implicated in 15-1588?
Orange Book mapping requires:
- Listing number(s)
- Patent expiration dates
- Whether listed patents are drug-substance, drug-product, or method-of-use
- Whether any listed patents are co-owned, assigned, or licensed
No Orange Book listing identifiers or patent numbers are provided.
When does exclusivity or patent protection for the litigated product expire?
Exclusivity exposure requires:
- Patent expiration dates (all listed patents)
- 5-year New Chemical Entity, 3-year new clinical investigation, pediatric exclusivity
- Potential extensions under 35 U.S.C. § 156
- Whether earlier paragraph IV actions triggered launch-blocking outcomes
Without product/patent identification, expiration cannot be calculated.
What Paragraph IV risks did Teva face in this litigation?
Paragraph IV analysis requires:
- Whether Teva certified under § 313(b) as to invalidity or non-infringement
- Whether the asserted patents were adjudged not infringed or invalid
- Whether the decision resulted in an automatic 180-day exclusivity forfeiture or settlement
No Paragraph IV notice details are included.
Did Warner Chilcott and Teva reach a settlement, and what were the entry terms?
Settlement terms drive commercial timelines:
- Entry dates
- Carve-outs for future strengths/dosage forms
- Design-around obligations
- Licensing royalties and audit rights
- Commitment to non-enforcement of specific claims
A docket-only reference does not provide settlement terms.
How does Federal Circuit 15-1588 compare with other Warner Chilcott vs Teva cases?
This comparison requires:
- Known parallel disputes involving the same active ingredient or same patent family
- Whether outcomes align (affirmed validity vs reversal)
- Whether later cases cite this decision for claim scope or legal standards
No comparative case list is provided.
Key takeaways
- A litigation summary for Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc. (15-1588) must identify the asserted patents, procedural posture, and Federal Circuit disposition to support any accuracy-driven conclusions on infringement, validity, and exclusivity.
- The docket number alone does not supply the decision record required to produce a business-actionable litigation analysis.
FAQs
- What is the Federal Circuit’s final disposition in Warner Chilcott v. Teva, 15-1588, and did it affirm or reverse the district court?
- Which specific patent numbers and claims were asserted in 15-1588?
- Did claim construction in the district court control the Federal Circuit outcome, and which terms were construed?
- What Orange Book listed patents correspond to the asserted Warner Chilcott patents in this appeal?
- Did the outcome of 15-1588 trigger a launch date, block a launch, or change 180-day exclusivity status?
References (APA)
No sources were provided or identified for docket 15-1588, asserted patents, or the decision text; therefore no citations can be listed.
